Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Chi

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Circulation|November 25, 2016
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)C Michael Gibson, Gerald Chi, Rim Halaby, et al.
The American Journal of Cardiology|April 2, 2019
Risk Factors, Imaging Findings, and Sex Differences in Spontaneous Coronary Artery DissectionShilpa Sharma, M Ihsan Kaadan, Jessica M Duran, et al.
Journal of Patient-Centered Research and Reviews|October 9, 2025
Understanding the Burden of Myocardial Infarction and Patient Preferences for Treatment: A Real-World Study Assessing Patients' Perspectives via an Online SurveyM Cecilia Bahit, Serge Korjian, Gerald Chi, et al.
Current Atherosclerosis Reports|May 7, 2022
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and FutureArzu Kalayci, C Michael Gibson, Paul M Ridker, et al.
Thrombosis and Haemostasis|November 13, 2018
Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX TrialArzu Kalayci, C Michael Gibson, Gerald Chi, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2019
Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX TrialC Michael Gibson, Lisa K Jennings, Gerald Chi, et al.
Journal of Thrombosis and Thrombolysis|July 10, 2014
D-Dimer elevation and adverse outcomesRim Halaby, Christopher J Popma, Ander Cohen, et al.
American Heart Journal|July 18, 2018
Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trialGerald Chi, Mathieu Kerneis, Arzu Kalayci, et al.
The American Journal of Cardiology|July 10, 2016
Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial)Yazan Daaboul, Serge Korjian, W Douglas Weaver, et al.
Journal of Thrombosis and Thrombolysis|June 27, 2018
Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary interventionGerald Chi, Megan K Yee, Arzu Kalayci, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Circulation|November 25, 2016
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)C Michael Gibson, Gerald Chi, Rim Halaby, et al.
The American Journal of Cardiology|April 2, 2019
Risk Factors, Imaging Findings, and Sex Differences in Spontaneous Coronary Artery DissectionShilpa Sharma, M Ihsan Kaadan, Jessica M Duran, et al.
Journal of Patient-Centered Research and Reviews|October 9, 2025
Understanding the Burden of Myocardial Infarction and Patient Preferences for Treatment: A Real-World Study Assessing Patients' Perspectives via an Online SurveyM Cecilia Bahit, Serge Korjian, Gerald Chi, et al.
Current Atherosclerosis Reports|May 7, 2022
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and FutureArzu Kalayci, C Michael Gibson, Paul M Ridker, et al.
Thrombosis and Haemostasis|November 13, 2018
Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX TrialArzu Kalayci, C Michael Gibson, Gerald Chi, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2019
Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX TrialC Michael Gibson, Lisa K Jennings, Gerald Chi, et al.
Journal of Thrombosis and Thrombolysis|July 10, 2014
D-Dimer elevation and adverse outcomesRim Halaby, Christopher J Popma, Ander Cohen, et al.
American Heart Journal|July 18, 2018
Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trialGerald Chi, Mathieu Kerneis, Arzu Kalayci, et al.
The American Journal of Cardiology|July 10, 2016
Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial)Yazan Daaboul, Serge Korjian, W Douglas Weaver, et al.
Journal of Thrombosis and Thrombolysis|June 27, 2018
Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary interventionGerald Chi, Megan K Yee, Arzu Kalayci, et al.
Pageof 10